Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity

Annals of Surgical Oncology

Volumn 19, Issue 6, 2012, Pages 1800-1807

  Olofsson, R ^a   Bergh, P ^a   Berlin, O ^a   Engstrom K ^a   Gunterberg, B ^a   Hansson, M ^a   Lindner P ^a   Mattsson, J ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AMPUTATION; ANGIOSARCOMA; ANKLE; ARM; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER SURGERY; CONTROLLED STUDY; ELBOW; EPITHELIOID HAMANGIOENDOTHELIOMA; EXTRASKELETAL MYXOID CHONDROSARCOMA; FEMALE; FIBROSARCOMA; FOLLOW UP; FOOT; HISTOPATHOLOGY; HUMAN; ISOLATED LIMB PERFUSION; KNEE; LEG; LIMB PERFUSION; LIMB SALVAGE; LOWER LEG; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MYXOFIBROSARCOMA; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA; TREATMENT RESPONSE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTRACORPOREAL CIRCULATION; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIMB SALVAGE; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84865139203     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2196-z     Document Type: Article

References (36)

1. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54:94-109. (Pubitemid 38519419)
2. Bauer HC, Trovik CS, Alvegard TA, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1, 851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2001;72:150-9. (Pubitemid 32405276)
3. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
4. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756-64.
5. Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoad-juvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26:669-78.
6. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic isolated perfusion with low-dose TNFalpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas. J Chemother. 2004;16(Suppl. 5):58-61. (Pubitemid 40052993)
7. Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol. 2005;16:1061-8. (Pubitemid 41418306)
8. Di Filippo F, Giacomini P, Rossi CR, et al. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo. 2009;23:363-7.
9. Lev-Chelouche D, Abu-Abeid S, Kollander Y, et al. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and mel-phalan. J Surg Oncol. 1999;70:185-9. (Pubitemid 29147169)
10. Broders A, Hargrave R, Meyerding H. Pathological features of soft tissue fibrosarcoma with special reference to the grading of its malignancy. Surg Gynecol Obstet. 1939;69:267.
11. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonre-sectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14:2653-65. (Pubitemid 26329649)
12. Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H. Isolated regional perfusion in malignant melanoma of the extremities. World J Surg. 1987;11:527-33. (Pubitemid 17137108)
13. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
14. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-10. (Pubitemid 13147887)
15. Aksnes LH, Bauer HC, Jebsen NL, et al. Limb-sparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br. 2008;90:786-94. (Pubitemid 351859809)
16. Pardasaney PK, Sullivan PE, Portney LG, Mankin HJ. Advantage of limb salvage over amputation for proximal lower extremity tumors. Clin Orthop Relat Res. 2006;444:201-8. (Pubitemid 44616855)
17. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ''high-risk'' adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096-103.
18. Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre-versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol. 2010;17:1367-74.
19. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11:561-70.
20. Muramatsu K, Ihara K, Miyoshi T, et al. Clinical outcome of limb-salvage surgery after wide resection of sarcoma and femoral vessel reconstruction. Ann Vasc Surg. 2011;25:1070-7.
21. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003;98:1483-90. (Pubitemid 37151504)
22. Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer. 2006;106:1776-84.
23. Thijssens KM, van Ginkel RJ, Pras E, et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol. 2006;13:518-24.
24. Cherix S, Speiser M, Matter M, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol. 2008;98:148-55.
25. Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol. 2007;14:230-8. (Pubitemid 44954294)
26. Pennacchioli E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol. 2007;14:553-9. (Pubitemid 46175300)
27. Bonvalot S, Rimareix F, Causeret S, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol. 2009;16:3350-7.
28. Lasithiotakis K, Economou G, Gogas H, et al. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Oncol Rep. 2010;23:1077-83.
29. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist. 2008;13(Suppl. 2):32-40.
30. Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009;251:447-56.
31. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl. 1):122S-50S.
32. 18F-fluorodeoxyt- hymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med. 2007;48:367-72. (Pubitemid 47604918)
33. Stener B. Musculoskeletal tumor surgery in Göteborg. Clin Orthop Relat Res. 1984(191):8-20.
34. Casali PG, Blay JY. Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v198-203.
35. Engstrom K, Bergh P, Cederlund CG, et al. Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology. Acta Oncol. 2007;46:838-45. (Pubitemid 47123772)
36. Deroose JP, Burger JW, van Geel AN, et al. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann Surg Oncol. 2011;18:321-7.